Page last updated: 2024-11-06

bezitramide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bezitramide: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID61791
CHEMBL ID2104149
CHEBI ID135794
SCHEMBL ID25733
MeSH IDM0045525

Synonyms (40)

Synonym
brn 0905485
bezitramide [inn:ban:dcf]
1-(3-cyano-3,3-diphenylpropyl)-4-(2-oxo-3-propionyl-1-benzimidazolinyl)piperidine
bezitramidum [inn-latin]
bezitramida [inn-spanish]
dea no. 9800
2-benzimidazolinone, 1-(1-(3-cyano-3,3-diphenylpropyl)-4-piperidyl)-3-propionyl-
einecs 239-335-4
1-(1-(3-cyano-3,3-diphenylpropyl)-4-piperidyl)-3-propionyl-2-benzimidazolinone
benzitramide
r-4845
r 4845
burgodin
burgodin (tn)
D07289
15301-48-1
bezitramide (inn)
DB01459
bezitramide
CHEBI:135794
4-[4-(2-oxo-3-propanoylbenzimidazol-1-yl)piperidin-1-yl]-2,2-diphenylbutanenitrile
ids-nb-007
CHEMBL2104149
n02ac05
5-24-02-00382 (beilstein handbook reference)
3kxw0y310i ,
unii-3kxw0y310i
bezitramidum
bezitramida
bezitramide [mi]
bezitramide [inn]
bezitramide [mart.]
bezitramide [who-dd]
SCHEMBL25733
2h-benzimidazol-2-one, 1-[1-(3-cyano-3,3-diphenylpropyl)-4-piperidinyl]-1,3-dihydro-3-(1-oxopropyl)-
4-[4-(2-oxo-3-propionyl-2,3-dihydro-1h-benzimidazol-1-yl)-1-piperidinyl]-2,2-diphenylbutanenitrile #
FLKWNFFCSSJANB-UHFFFAOYSA-N
1-[1-(3-cyano-3,3-diphenylpropyl)-4-piperidinyl]-1,3-dihydro-3-(1-oxopropyl)-2h-benzimidazol-2-one
DTXSID90165197
Q794409
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (62.50)18.7374
1990's2 (25.00)18.2507
2000's1 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.81 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.11 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (10.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (10.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]